Dare Bioscience, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0M | $9,784 | $2.8M | $10.0M | $0 |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M |
| Operating expenses | $14.3M | $23.5M | $33.7M | $41.4M | $39.1M |
| Cost of revenue | $295,799 | $0 | — | — | — |
| Cash from operations | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M |
| Capital expenditure | $385,278 | $573,046 | $629,430 | $63,069 | $14,524 |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M |
Shares outstanding 15.0M · Free float 25.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.